MDS to Commercialize Signature BioScience s Proteomics Technology | GenomeWeb

NEW YORK, Aug 16 – Canadian life science company MDS has agreed to develop and commercialize Signature BioScience's microwave spectroscopy instrumentation, the companies announced.

MDS will pay Signature Biosciences $10 million upfront and will provide additional milestone and royalty payments in exchange for exclusive license rights to commercialize the microwave spectroscopy instrumentation and peripherals. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.